Editorial: Targeting dimethylarginine dimethylaminohydrolases in pulmonary arterial hypertension: A new approach to improve vascular dysfunction?

Circulation

Volumn 123, Issue 11, 2011, Pages 1156-1158

  Zweier, Jay L ^a,b   Talukder, M A Hassan ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

cGMP; dimethylarginine dimethylaminohydrolase; Editorials; methylarginine; nitric oxide; nitric oxide synthase; phosphodiesterase inhibitor

Indexed keywords

DIMETHYLARGININASE; ENDOTHELIN RECEPTOR ANTAGONIST; N(G),N(G) DIMETHYLARGININE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; SILDENAFIL; TOLAFENTRINE; UNCLASSIFIED DRUG; AMIDASE; ARGININE; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; NAPHTHYRIDINE DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EDITORIAL; ENZYME INHIBITION; HUMAN; LUNG ARTERY PRESSURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; DRUG ANTAGONISM; METABOLISM; NOTE; PHYSIOLOGY;

AMIDOHYDROLASES; ARGININE; HUMANS; HYPERTENSION, PULMONARY; NAPHTHYRIDINES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITORS;

EID: 79953042859     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.017038     Document Type: Editorial

References (20)

1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119: 2250-2294.
2. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164-172.
3. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
4. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001;88:756-762. (Pubitemid 32429970)
5. Dweik RA. The lung in the balance: arginine, methylated arginines, and nitric oxide. Am J Physiol Lung Cell Mol Physiol. 2007;292:L15-L17. (Pubitemid 46103425)
6. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
7. Zakrzewicz D, Eickelberg O. From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulm Med. 2009;9:5.
8. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res. 1999;43: 542-548. (Pubitemid 29369253)
9. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007;293:H3227-H3245. (Pubitemid 350230862)
10. Wagner RS, Smith CJ, Taylor AM, Rhoades RA. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther. 1997;282:1650-1657. (Pubitemid 27408352)
11. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5:689-702. (Pubitemid 44151606)
12. Pullamsetti SS, Savai R, Schaefer MB, Wilhelm J, Ghofrani HA, Weissmann N, Schudt C, Fleming I, Mayer K, Leiper J, Seeger W, Grimminger F, Schermuly RT. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. Circulation. 2011;123:1194-1204.
13. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. 2007;282:879-887. (Pubitemid 47076535)
14. Druhan LJ, Forbes SP, Pope AJ, Chen CA, Zweier JL, Cardounel AJ. Regulation of eNOS-derived superoxide by endogenous methylarginines. Biochemistry. 2008;47:7256-7263. (Pubitemid 351956374)
15. Cardounel AJ, Xia Y, Zweier JL. Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin. J Biol Chem. 2005;280:7540-7549. (Pubitemid 40349646)
16. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature. 2010;468: 1115-1118.
17. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003;4:41-51. (Pubitemid 38234494)
18. Cooke JP. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis. Eur J Clin Pharmacol. 2006;62(Suppl 1):115-121.
19. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62:525-563.
20. Das A, Xi L, Kukreja RC. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem. 2008;283:29572-29585.